© ILTCI Conference 2017-18 - All Rights Reserved.
The 18th Annual Intercompany
Long-Term Care Insurance Conference
March 18-21, 2018 - Paris Hotel & Casino - Las Vegas, NV
Managing Alzheimer’s Disease &
Understanding the Latest in
Alzheimer’s Research
This
two
part
session
will
begin
with
Managing
Alzheimer’s
Disease:
Resources
and
Support
for
All
Stages
of
the
Disease.
This
topic
will
include
facts
and
figures
on
the
financial
as
well
as
physical
and
emotional
impacts
of
Alzheimer’s
and
dementia
on
the
U.S.
and
families.
The
session
explores
the
benefits
of
early
detection,
how
to
address
a
diagnosis
of
Alzheimer’s
disease,
stages
of
the
disease
and
will
provide
best
practices
for
families
when
planning
and/or
dealing
with
the
disease.
Most
importantly,
the
various
programs
and
services
of
the
Alzheimer’s
Association
available
to
help
individuals
will
be
reviewed.
Presented
by
Ruth
Kolb
Drew,
Director
of
Information
and
Support Services at the Alzheimer's Association. (75 minute session)
Part
two
will
cover
Understanding
the
Latest
in
Alzheimer’s
Research.
Every
week
there
is
something
in
the
news
about
Alzheimer’s
research,
treatments
or
prevention.
Join
James
A.
Hendrix,
PhD,
Director,
Global
Science
Initiatives
at
the
Alzheimer's
Association
to
hear
the
latest
in
what
is
real
and
promising
in
the
fight
against
Alzheimer’s.
(75
minute
session)
Join
us
Wednesday,
March
21st
from
9am-12pm
for
this
great session!
Ruth
Drew,
is
the
Director
of
Information
and
Support
Services
at
the
home
office
of
the
Alzheimer's
Association
in
Chicago,
where
she
leads
the
work
of:
•
The
National
Alzheimer’s
Association
24-hour
Helpline,
which
offers
information
and
counseling
to
over
300,000
callers
each
year,
in
cooperation
with
78
chapters
across
the
country.
The
Helpline
assists
people
affected
by
Alzheimer's
disease,
their
family
members
and
caregivers.
Drew
authored
and
directs
a
5-year,
$4.9
million
grant
from
the
Administration
on
Community
Living
which
helps
fund
the
Helpline.
•
The
Green-Field
Library,
the
primary
dementia-focused
library
in
the
US.
Drew
joined
the
Alzheimer’s
Association
in
2004
and
served
as
Program
Director
at
a
chapter
before
moving
to
the
national
office
in
2010.
She
led
the
development
of
family
education
programs
and
online
resources
used
across
the
country
to
increase
awareness,
information
and
support
to
all
affected.
She
is
a
licensed
counselor
with
a
master’s
degree
in
Counseling
Psychology
and
experience
in
inpatient
and
agency
settings.
She
has
presented
at
many
national
and
regional
conferences,
written
and
directed
numerous
programs
and
grant
projects,
and
educated
thousands
of
family
caregivers
and
professionals
concerning
caring
for
people
with
Alzheimer’s
and
other
dementias.
Drew
has
a
personal
interest
in
the
work
of
the
Alzheimer’s
Association
because
her
father
has
the
disease,
and
she
is
honored
to
help other families impacted by Alzheimer’s.
James
A.
Hendrix,
Ph.D.,
is
director,
global
science
initiatives,
at
the
Alzheimer’s
Association.
As
a
member
of
the
Medical
and
Scientific
Relations
Division,
he
provides
leadership
on
specific
domestic
and
international
efforts
focused
on
advancing
the
division’s
science
agenda.
A
critical
element
of
his
role
is
to
manage
industry
consortia
such
as
the
Alzheimer’s
Association
Research
Roundtable
(AARR);
lead
the
Global
Biomarker
Standardization
Consortium;
manage
and
direct
future
meeting
efforts
and
output;
and
assist
with
the
coordination
of
the
$100
million
dollar
Imaging
Dementia-Evidence
for
Amyloid
Scanning
(IDEAS)
Study
on
the
clinical
usefulness
of
amyloid
PET
imaging.
Dr.
Hendrix
received
his
Ph.D.
and
a
postdoctoral
fellowship
from
Colorado
State
University.
Before
joining
the
Alzheimer’s
Association,
Dr.
Hendrix
was
a
pharmaceutical
scientist
with
a
focus
on
drug
discovery
for
CNS
diseases.
Dr.
Hendrix
spent
18
years
working
at
Sanofi-Aventis
and
predecessor
companies,
where
he
rose
to
level
of
senior
director,
U.S.
site
head
for
CNS
research.
He
also
spent
two
years
working
in
the
biotech
industry
with
various
companies,
including
Oligomerix,
which
is
focused
on
tau
for
the
treatment
of
Alzheimer’s disease.